Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents for Long-Coronary Lesions

Study Overview
=================
Brief Summary
-----------------
This randomized study is a multi-center, randomized, study to compare the efficacy of biolimus A9-eluting stent (Nobori) vs. everolimus-eluting stent (Promus Element) for long coronary lesions.

Detailed Description
-----------------
Following angiography, patients with significant diameter stenosis >50% and lesion length(> 25mm) requiring single or multiple long-stent placement(total stent length 28mm) by visual estimation and eligible for LONG-DES V trial inclusion and exclusion criteria will be randomized 1:1 to a) NOBORI and b) PROMUS-ELEMENT stent by the stratified randomization method.

Official Title
-----------------
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-V:Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: Biolimus A9-eluting stent
* Device: Everolimus-eluting stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient must be at least 18 years of age. Significant native coronary artery stenosis (>50% by visual estimate) with lesion length of more than 25mm, which requiring single or multiple long stent placement (>=28mm) Patients with silent ischemia, stable or unstable angina pectoris, ad Non-ST-elevation myocardial infarction The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site. Exclusion Criteria: Any contraindication to any of the following medications: aspirin, heparin, clopidogrel, stainless steel, contrast agents, sirolimus, or everolimus. An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment. Acute ST-segment-elevation MI or cardiogenic shock Terminal illness with life expectancy <1 year Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. In-stent restenosis at target vessel (either bare metal stent or drug-eluting stent segment, non-target vessel ISR is permitted) Patients with EF<30%. Serum creatinine level >=3.0mg/dL or dependence on dialysis. Patients with left main stem stenosis (>50% by visual estimate).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Biolimus A9-eluting stent<br>NOBORI stent | Device: Biolimus A9-eluting stent<br>* drug-eluting stent<br>* Other names: NOBORI stent;|
| Active Comparator: Everolimus-eluting stent<br>PROMUS ELEMENTE stent | Device: Everolimus-eluting stent<br>* drug-eluting stent<br>* Other names: PROMUS ELEMENT stent;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-segment late luminal loss |  | 9 month angiographic follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death (all-cause and cardiac) |  | 1 year | 
| Myocardial infarction |  | 1 year | 
| stent thrombosis(ARC criteria) |  | 1 year | 
| target-lesion revascularization |  | 1 year | 
| target-vessel revascularization |  | 1 year | 
| Procedural success |  | at 1 day | 
| Death (all-cause and cardiac) |  | one month | 
| Death (all-cause and cardiac) |  | 9 months | 
| Myocardial infarction |  | one month | 
| Myocardial infarction |  | 9 months | 
| Composite of death or MI |  | one month | 
| Composite of death or MI |  | 9 months | 
| Composite of death or MI |  | 1 year | 
| Composite of cardiac death or MI |  | one month | 
| Composite of cardiac death or MI |  | 9 months | 
| Composite of cardiac death or MI |  | 1 year | 
| target-lesion revascularization |  | one month | 
| target-lesion revascularization |  | 9 months | 
| target-vessel revascularization |  | one month | 
| target-vessel revascularization |  | 9 months | 
| stent thrombosis(ARC criteria) |  | one month | 
| stent thrombosis(ARC criteria) |  | 9 months | 
| In-stent late loss |  | 9 month angiographic follow-up | 
| 8. Target-vessel failure (death from any cause, myocardial infarction, and ischemic-driven target-vessel revascularization) |  | 12 months | 
| In-stent and in-segment restenosis |  | 9 month angiographic follow-up | 
| Angiographic pattern of restenosis |  | 9 month angiographic follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary disease, stent